Clinical Trial

Neoadjuvant Therapy With Nab-paclitaxel and Cisplatin for Locally Advanced Esophageal Squamous Cell Carcinoma

Study acronym: NTNC
Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated October 10, 2023 (before its estimated June 24, 2026 completion). Its status may not reflect the trial's current state.
Summary
To verify the role of nab-paclitaxel in neoadjuvant therapy for esophageal squamous cell carcinoma, the investigators designed a prospective, randomized, controlled , multicente phase II trial, to investigate the efficacy and safety of nab-paclitaxel combined with cisplatin as neoadjuvant therapy followed by surgery versus surgery alone for esophageal squamous cell carcinoma.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2019-05-23; most recent amendment 2023-10-06.
Status change: Enrolling by Invitation → Recruiting 2019-08-14
Trial Details
NCT Number NCT03964753
Lead Sponsor Hebei Medical University Fourth Hospital
Conditions Esophageal Squamous Cell Carcinoma
Enrollment 202 participants
Start Date 2019-04-24
Primary Completion 2026-06-24 (estimated)
Study Completion 2026-12-24 (estimated)
Updated on ClinicalTrials.gov 2023-10-10